Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor.

Kjetil BoyeLudmila GorunovaBastian GunawanIvar HomplandBjoern SanderIoannis PanagopoulosClaus LangerMariola Monika GolasSverre HeimLászló FüzesiToto HølmebakkFrancesca Micci

Published in: JCO precision oncology (2023)

Genomic tumor complexity is an independent prognostic biomarker in localized, high-risk GIST. Recurrences were infrequent for tumors with simple karyotypes. De-escalation of adjuvant imatinib treatment should be explored in patients with cytogenetically simple GISTs.

Keyphrases

early stage
randomized controlled trial
chronic myeloid leukemia
clinical trial
dna methylation
open label
replacement therapy